Neal D. Shore, MD, FACS, Atlantic Urology Clinics, discusses glypican-1 as a biomarker for prostate cancer.
Neal D. Shore, MD, FACS, medical director, Carolina Urologic Research Center, managing partner, Atlantic Urology Clinics, discusses glypican-1 as a biomarker for prostate cancer.
Glypican-1 is a new receptor found to be involved in many different growth processes of malignant cells, says Shore. It is demonstrable in blood, urine, serum, and plasma. He and his colleagues conducted a preliminary pilot study of 300 patients, and they were able to find a cut point, where they could see a very high specificity for demonstrating patients who had cancer versus those who did not.
Traditionally, other biomarkers have had a fairly high sensitivity for true positives or true negatives, but they do not have the specificity at the same time, adds Shore.
Advances in Subsequent Therapies Shake Up Sequencing of ccRCC Treatment
April 25th 2024With the approval of belzutifan and other newer data for treating patients with recurrent renal cell carcinoma, the state of subsequent therapies is advancing beyond the reuse of frontline options with impacts on duration of response and quality of life.
Read More
Ornstein Advises on Starting Dose and Management of Lenvatinib in RCC
April 21st 2024During a Case-Based Roundtable® event, Moshe Ornstein, MD, MA, provided guidance on dosing and toxicity concerns in a patient treated with lenvatinib plus pembrolizumab for advanced renal cell carcinoma.
Read More